Category: Uncategorized

AIBILI is happy to participate in the Azores Health Summit which will take place on 12-13/05/2022. Our President, Prof. Conceição Lobo, will share AIBILI’s experience in the development and implementation of diabetic retinopathy screening programmes using artificial intelligence. This participation will be complemented by João Diogo Ramos from our partnering company Retmarker SA.

We are honoured to see our recent US Patent published representing another major milestone in AIBILI’s history. This patent US 11,2354,591 B2 follows the EU Patent EP3289565A1 that was received in August 2020.

The team lead by the inventors José Cunha-Vaz and Torcato Santos have developed a method and device that detects and quantifies abnormal increases of retinal extra cellular space using sites of low optical reflectivity from optical coherence tomography (OCT).

This non-invasive method detects changes in the blood-retinal barrier enabling timely treatment and therapy validation in the early stages of diabetic retinopathy.

Do not miss the opportunity to hear about AIBILI Data Centre and its relevance for clinical research development.

Carlos Domingues, AIBILI DataCentre Director will participate in this conference taking place on May 19, 2022, in Porto, Portugal.

This AIBILI infrastructure is the unique DataCentre in the Peninsula Iberia certified by ECRIN.

AIBILI has participated through his Projects and Tech Transfer Manager, Daniel Sanches Fernandes, in the EATRIS PORTUGAL Hub Meeting on April 27, 2022 at INFARMED, I.P. in Lisbon.

The AIBILI 2021 report is now available. Please download it here.

Congratulations to our Investigators Cláudia Farinha and Patrícia Barreto that were awarded with the Prémio Plácido during the 64th Congress of the Portuguese Ophthalmology Society with the paper GENETIC CHARACTERIZATION OF AMD IN THE COIMBRA EYE STUDY – Common and Rare Risk Variants & Genetic Risk Score (GRS) .

 

This is the first genetic study in AMD in a Portuguese population. According to our results, several variants were found to be associated with the presence and progression to AMD in our cohort, while others were protective. Furthermore, damaging rare variants in the CFH gene were cumulatively more common in AMD patients and the GRS was significantly different between AMD and non-AMD individuals. Our study adds new information regarding the genetics of AMD in a European population, which can be used for comparison with other populational cohorts and further expand the knowledge of AMD pathophysiology.

During the 8th Forum on Management of Research Data that will take place in Coimbra, Portugal, on November 25-26, 2021, AIBILI will be presenting two talks by Carlos Domingues and Pier Basile. Program available here (Programa | Fórum de Gestão de Dados de Investigação (rcaap.pt))

Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de novas medidas para minimizar o risco de eventos adversos cardiovasculares major na utilização de Tofacitinib (Xeljanz▼), do risco de reações adversas cutâneas graves (SCARs) com atezolizumab (Tecentriq▼) e outros medicamentos anticancerígenos imunoestimuladores e também dos relatos de doença pulmonar intersticial e pneumonite com inibidores da CDK4/6. Destaca-se ainda informação sobre as vacinas aprovadas e em avaliação para a prevenção da COVID-19, assim como os tratamentos em avaliação e aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no segundo e terceiro trimestres de 2021.

Consulte: Farmacovigilancia – Atualizacoes de segurança de Medicamentos Vol8 N2 e 3

Our honorary president, Prof. José Cunha-Vaz has spoken to the newspaper “Campeão das Provincias” in the scope of the #worldSightDay, celebrated today, October 14!

In this communication, Prof. Cunha-Vaz raises the awareness for the current need on visual health, not only for diseases related to aging as diabetic retinopathy, glaucoma or AMD, but particularly for the current eye care required due to visual problems caused by the excessive use of technologic devices.

Link

We are happy to announce that AIBILI is part of the PTCentroDiH – a regional hub to support small and medium-sized enterprises addressing the digital transformation challenge ahead.

 

PTCentroDiH aims to act as a one-stop-shop to foster competitiveness, innovation and territorial cohesion in the Centro Region of Portugal. Among 21 entities AIBILI will specifically contribute with cybersecurity and artificial intelligence services.

 

AIBILI has a Data Centre certified by ECRIN (unique in the Iberian Peninsula certified by this standard) that gives PTCentroDiH a strategic position in clinical research, and data management in accordance with the regulations.

 

AIBILI has also extensive experience in algorithms’ development, which that allows the automatic detection of injuries/ anomalous conditions in ophthalmic images, as well as in the development of projects within the scope of artificial intelligence.

 

For more information please visit www.ptcentrodih.pt